Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Adds Myfortic To Transplant Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis gained approval for Myfortic (mycophenolate sodium) Feb. 27 for use in kidney transplantation

You may also be interested in...



Novartis’ Myfortic Can Increase Risk Of Fetal Damage, FDA Finds

The finding for the organ transplant drug follows by a month a similar warning about Roche competitor, CellCept.

Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint

The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel